NEXGEL, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
NEXGEL, INC. (NXGL) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $1.06 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-05-14
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $1.06M.
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$615.00K.
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$281.00K.
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$314.00K.
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$749.00K.
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$893.00K, a 155.85% decline from fiscal 2023.
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $1.60M.
- NEXGEL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$12.25M, a 191.97% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | -$749.00K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $51.00K 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | -$1.08M 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | -$615.00K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$893.00K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$1.64M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$1.63M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$281.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $1.60M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $2.17M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $2.59M 10-Q · filed 2024-08-19 | |||
| 2023-03-31 | -$314.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$12.25M 10-K · filed 2024-04-10 | |||
| 2022-09-30 | -$11.92M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$8.93M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$2.83M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $13.32M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $1.22M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $350.00K 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $1.04M 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | -$229.00K 10-K · filed 2022-03-21 | |||
| 2020-09-30 | -$104.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$28.00K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$41.00K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $261.00K 10-K · filed 2021-03-31 | |||
| 2019-09-30 | $88.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $186.00K 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $0.00 10-K/A · filed 2020-04-03 | |||
| 2018-09-30 | $0.00 10-Q · filed 2020-01-28 | |||
| 2018-06-30 | $0.00 10-Q · filed 2019-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |